Apimeds Pharmaceuticals US (APUS) Assets Average (2025)

Apimeds Pharmaceuticals US (APUS) posted Assets Average of $86.7 million for Q4 2025, up 776.07% on a QoQ basis from $9.9 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Assets Average (2025) Analysis & Trends

Apimeds Pharmaceuticals US's Assets Average history runs 1 years deep, the most recent figure standing at $86.7 million for Q4 2025.

Quarterly Assets Average changed N/A year-over-year to $86.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $86.7 million (changed N/A YoY) and the FY2025 annual result came in at $82.1 million, up 37634.85% from the prior year.
Assets Average was $86.7 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $9.9 million in the prior quarter.
Across five years, Assets Average topped out at $86.7 million in Q4 2025 and bottomed at $136480.5 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets Avg. (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	43.72 Bn
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	40.39 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	15.32 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	99.52 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	7.30 Bn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	68.63 Bn
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	37.01 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	4.77 Bn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	13.29 Bn
10	Apimeds Pharmaceuticals US	8.17 Mn	8.17 Mn	-	86.72 Mn

Download Data